Axinn Obtains Favorable Decision in FDA Suit
January 15, 2013
Axinn secured a favorable outcome for client Alvogen Inc. in ViroPharma Inc’s case against the U.S. Food and Drug Administration regarding generic forms of the antibiotic Vancocin (vancomycin). The Axinn team assisted Alvogen Inc. in intervening on the side of the government in order to allow Alvogen to continue to market its generic vancomycin product under its approved Abbreviated New Drug Application.
Judge Huvelle’s Memorandum Opinion stated that “the FDA acted well within its discretion in denying three-year exclusivity to ViroPharma and in approving the ANDAs of intervenor-defendants.”
To subscribe to our publications, click here.
Featured Insights
Featured Insights
IPWatchdog Sixth Annual Live Conference
Speaking Engagement
Intellectual Property
ABA White Collar Crime Institute 2026
Speaking Engagement
GCR Live Cartels: 2026
Speaking Engagement
Antitrust
SCCE 14th Annual European Compliance & Ethics Institute
Speaking Engagement
Antitrust
Noerr Competition Day 2026
Speaking Engagement
Antitrust
Axinn Antitrust Insight: "New" HSR Form Remains in Effect For Now – Fifth Circuit Temporarily Freezes District Court Order that Vacated the New HSR Rule
Axinn Viewpoints
Antitrust
Consumer Brands CPG Legal Forum 2026
Speaking Engagement
NBA CLS 39th Annual Corporate Counsel Conference
Sponsorship
Antitrust
University of Pennsylvania Journal of Business Law Annual Symposium 2026
Speaking Engagement
Antitrust
Chambers Recognizes Axinn’s Antitrust Practice in 2026 Global Rankings — With New Recognition in Cartel Category
Awards & Recognitions
Antitrust
